First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
BackgroundThe aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer.MethodsThis study established a partition survival model for three he...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.602185/full |
| _version_ | 1818728600720900096 |
|---|---|
| author | Longfeng Zhang Yongfu Hang Maobai Liu Na Li Hongfu Cai |
| author_facet | Longfeng Zhang Yongfu Hang Maobai Liu Na Li Hongfu Cai |
| author_sort | Longfeng Zhang |
| collection | DOAJ |
| description | BackgroundThe aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer.MethodsThis study established a partition survival model for three health states, metastasis probability, and safety data based on the CASPIAN clinical trial. The health utility value was mainly derived from the published literature. Only direct medical costs were considered. Sensitivity analyses were conducted to assess the robustness of the incremental cost per quality-adjusted life year (QALY).ResultsDurvalumab plus platinum–etoposide increased QALY by 0.220 compared to that observed with platinum–etoposide only. The cost increased by $78,198.75 and the incremental cost per QALY increased by $355,448.86. One-way and probability sensitivity analyses indicated that the model parameters varied within a limited range and had no significant effect on the results.ConclusionsAlthough durvalumab plus platinum–etoposide can improve quality of life, it also substantially increases the cost of medical treatment. Under a willingness-to-pay threshold of $100,000, durvalumab does not have a cost-effective comparative advantage. |
| first_indexed | 2024-12-17T22:32:35Z |
| format | Article |
| id | doaj.art-3b3c2ef57bea435f88cc9b1bd22ce9e5 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-17T22:32:35Z |
| publishDate | 2020-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3b3c2ef57bea435f88cc9b1bd22ce9e52022-12-21T21:30:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-12-011010.3389/fonc.2020.602185602185First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness AnalysisLongfeng Zhang0Yongfu Hang1Maobai Liu2Na Li3Hongfu Cai4Department of Thoracic Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Medical University, Fuzhou, ChinaDepartment of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, ChinaDepartment of Pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, ChinaDepartment of Pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, ChinaBackgroundThe aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer.MethodsThis study established a partition survival model for three health states, metastasis probability, and safety data based on the CASPIAN clinical trial. The health utility value was mainly derived from the published literature. Only direct medical costs were considered. Sensitivity analyses were conducted to assess the robustness of the incremental cost per quality-adjusted life year (QALY).ResultsDurvalumab plus platinum–etoposide increased QALY by 0.220 compared to that observed with platinum–etoposide only. The cost increased by $78,198.75 and the incremental cost per QALY increased by $355,448.86. One-way and probability sensitivity analyses indicated that the model parameters varied within a limited range and had no significant effect on the results.ConclusionsAlthough durvalumab plus platinum–etoposide can improve quality of life, it also substantially increases the cost of medical treatment. Under a willingness-to-pay threshold of $100,000, durvalumab does not have a cost-effective comparative advantage.https://www.frontiersin.org/articles/10.3389/fonc.2020.602185/fulldurvalumabplatinum–etoposidecost-effectivenessextensive-stage small-cell lung cancersmall cell lung cancer |
| spellingShingle | Longfeng Zhang Yongfu Hang Maobai Liu Na Li Hongfu Cai First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis Frontiers in Oncology durvalumab platinum–etoposide cost-effectiveness extensive-stage small-cell lung cancer small cell lung cancer |
| title | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis |
| title_full | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis |
| title_fullStr | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis |
| title_full_unstemmed | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis |
| title_short | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis |
| title_sort | first line durvalumab plus platinum etoposide versus platinum etoposide for extensive stage small cell lung cancer a cost effectiveness analysis |
| topic | durvalumab platinum–etoposide cost-effectiveness extensive-stage small-cell lung cancer small cell lung cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2020.602185/full |
| work_keys_str_mv | AT longfengzhang firstlinedurvalumabplusplatinumetoposideversusplatinumetoposideforextensivestagesmallcelllungcanceracosteffectivenessanalysis AT yongfuhang firstlinedurvalumabplusplatinumetoposideversusplatinumetoposideforextensivestagesmallcelllungcanceracosteffectivenessanalysis AT maobailiu firstlinedurvalumabplusplatinumetoposideversusplatinumetoposideforextensivestagesmallcelllungcanceracosteffectivenessanalysis AT nali firstlinedurvalumabplusplatinumetoposideversusplatinumetoposideforextensivestagesmallcelllungcanceracosteffectivenessanalysis AT hongfucai firstlinedurvalumabplusplatinumetoposideversusplatinumetoposideforextensivestagesmallcelllungcanceracosteffectivenessanalysis |